Unit
- Lifecycle phases: The medical device development lifecycle consists of conceptualization, design and development, verification and validation, regulatory submission, manufacturing, and post-market surveillance. Each phase has specific deliverables and gate reviews to ensure progression.
- Stakeholder involvement: Early engagement with clinicians, patients, regulators, and payers is critical. User needs are gathered through interviews and observations to define design inputs that drive the entire development process.
- Design controls: FDA 21 CFR 820.30 and ISO 13485 require documented design plans, design inputs, design outputs, design reviews, verification, validation, and design transfer. These controls ensure traceability and systematic product realization.
- Regulatory strategy: Determining the device class (I, II, III) early influences the submission pathway. Class II devices often require a 510(k) submission showing substantial equivalence, while Class III devices need a Pre-Market Approval (PMA) with clinical data.
- Quality management integration: QMS elements like document control, training, and corrective actions are woven into each phase. A robust QMS reduces rework and accelerates time to market.
- Risk management integration: Per ISO 14971, risk analysis is performed continuously. Each design change triggers a re-evaluation of risks and benefits to patient safety.
- Verification and validation: Verification confirms design outputs meet design inputs (e.g., bench testing). Validation confirms the device meets user needs under actual or simulated use conditions (e.g., clinical studies).
- Post-market phase: After market release, the manufacturer must monitor complaints, perform periodic safety updates, and implement corrective actions. This feeds back into the lifecycle for continuous improvement.
- Clinical evaluation: A clinical evaluation plan outlines the approach for collecting and analyzing clinical data to support safety and performance. For higher risk devices, clinical investigations may be necessary. Existing clinical data from equivalent devices can be leveraged under certain conditions, reducing the need for de novo trials.
- Human factors engineering: Usability testing identifies use errors during simulated use with representative users. IEC 62366 requires iterative design and evaluation to minimize risks from user interface design. Formative and summative studies are conducted to validate that the device can be used safely and effectively.
- Reimbursement strategy: Early engagement with payers and health technology assessment bodies is crucial. Coding, coverage, and payment pathways affect market adoption. Evidence generation must address cost effectiveness and clinical utility to secure favorable reimbursement decisions and successful market uptake.
Code Example
Python
class DeviceLifecycle:
def __init__(self, device_class):
self.phase = 'concept'
self.device_class = device_class
self.risk_log = []
def progress_to(self, phase):
self.phase = phase
print(f'Moving to {phase} phase')
def add_risk(self, hazard, severity):
self.risk_log.append({'hazard': hazard, 'severity': severity})
# Example usage
device = DeviceLifecycle('Class II')
device.progress_to('design')
device.add_risk('electrical shock', 'critical')This Python class models a simplified lifecycle tracker. It stores device class, current phase, and risk items. In practice, such tracking is more detailed and integrated with a QMS software.
Quick Revision
- The lifecycle includes concept, design, development, validation, submission, production, and post-market phases.
- Design controls (FDA 21 CFR 820.30) mandate documentation and traceability.
- Early regulatory strategy based on device class reduces delays.
- Risk management is integrated throughout the lifecycle.